124 related articles for article (PubMed ID: 35715305)
21. Long-term clinical outcome and dosimetric comparison of tandem and ring versus tandem and ovoids intracavitary application in cervical cancer.
Atasever Akkas E; Altundag MB
J BUON; 2021; 26(3):698-706. PubMed ID: 34268923
[TBL] [Abstract][Full Text] [Related]
22. Vaginal dose assessment in image-guided brachytherapy for cervical cancer: Can we really rely on dose-point evaluation?
Limkin EJ; Dumas I; Rivin Del Campo E; Chargari C; Maroun P; Annède P; Petit C; Seisen T; Doyeux K; Tailleur A; Martinetti F; Lefkopoulos D; Haie-Meder C; Mazeron R
Brachytherapy; 2016; 15(2):169-76. PubMed ID: 26778755
[TBL] [Abstract][Full Text] [Related]
23. Preliminary survey of 3D image-guided brachytherapy for cervical cancer at representative hospitals in Asian countries.
Okonogi N; Wakatsuki M; Mizuno H; Fukuda S; Cao J; Kodrat H; Lau FN; Calaguas MJ; de Los Reyes RH; Chansilpa Y; Uddin AFMK; Adylkhanov T; Cho CK; Tsegmed U; Hoang NC; Ohno T; Nakano T; Kato S;
J Radiat Res; 2020 Jul; 61(4):608-615. PubMed ID: 32367130
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes of Computed Tomography-Based Volumetric Brachytherapy Planning for Cervical Cancer.
Simpson DR; Scanderbeg DJ; Carmona R; McMurtrie RM; Einck J; Mell LK; McHale MT; Saenz CC; Plaxe SC; Harrison T; Mundt AJ; Yashar CM
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):150-7. PubMed ID: 26130230
[TBL] [Abstract][Full Text] [Related]
25. Late rectal toxicity determined by dose-volume parameters in computed tomography-based brachytherapy for locally advanced cervical cancer.
Zhou YC; Zhao LN; Wang N; Hu J; Sun XH; Zhang Y; Li JP; Li WW; Liu JY; Wei LC; Shi M
Cancer Med; 2016 Mar; 5(3):434-41. PubMed ID: 26806114
[TBL] [Abstract][Full Text] [Related]
26. Ureteral stenosis after 3D MRI-based brachytherapy for cervical cancer - Have we identified all the risk factors?
Rodríguez-López JL; Ling DC; Keller A; Kim H; Mojica-Márquez AE; Glaser SM; Beriwal S
Radiother Oncol; 2021 Feb; 155():86-92. PubMed ID: 33065181
[TBL] [Abstract][Full Text] [Related]
27. Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies.
Murakami N; Kasamatsu T; Sumi M; Yoshimura R; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Ito Y; Itami J
Radiat Oncol; 2014 Jan; 9():31. PubMed ID: 24456669
[TBL] [Abstract][Full Text] [Related]
28. Electronic brachytherapy for postsurgical adjuvant vaginal cuff irradiation therapy in endometrial and cervical cancer: a retrospective study.
Kamrava M; Chung MP; Demarco J; Kayode O; Park SJ; Borja L; Chow L; Lee SP; Steinberg ML; Demanes DJ
Brachytherapy; 2013; 12(2):141-7. PubMed ID: 22748291
[TBL] [Abstract][Full Text] [Related]
29. The effect of lower urinary tract substructure doses on side effects of cervical cancer image-guided adaptive brachytherapy.
Azak C; Kavak G; Ertan F; Alioğlu F; Akkaş EA; Göksel F; Karakaya E
J Cancer Res Ther; 2023 Oct; 19(7):1825-1830. PubMed ID: 38376285
[TBL] [Abstract][Full Text] [Related]
30. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.
Zhang Y; Gomez G; Ascaso C; Herreros A; Fornes B; Mases J; Rochera J; Tagliaferri L; Sabater S; Torne A; Biete A; Rovirosa Á
Clin Transl Oncol; 2022 May; 24(5):875-881. PubMed ID: 34854030
[TBL] [Abstract][Full Text] [Related]
31. Deformable image registration for cervical cancer brachytherapy dose accumulation: Organ at risk dose-volume histogram parameter reproducibility and anatomic position stability.
Flower E; Do V; Sykes J; Dempsey C; Holloway L; Summerhayes K; Thwaites DI
Brachytherapy; 2017; 16(2):387-392. PubMed ID: 28161434
[TBL] [Abstract][Full Text] [Related]
32. Can we reduce dose to ureters as avoidance organs for MRI based brachytherapy for cervical cancer? A dosimetric feasibility study.
Koerner SA; Baig T; Kim H; Rodríguez-López J; Keller A; Beriwal S
Brachytherapy; 2022; 21(2):202-207. PubMed ID: 34980569
[TBL] [Abstract][Full Text] [Related]
33. Three-dimensional high dose rate intracavitary image-guided brachytherapy for the treatment of cervical cancer using a hybrid magnetic resonance imaging/computed tomography approach: feasibility and early results.
Beriwal S; Kannan N; Kim H; Houser C; Mogus R; Sukumvanich P; Olawaiye A; Richard S; Kelley JL; Edwards RP; Krivak TC
Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):685-90. PubMed ID: 21908180
[TBL] [Abstract][Full Text] [Related]
34. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction
Aguilera MDV; Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Garcia-Migue J; Cortes S; Agusti E; Camacho C; Zhang Y; Li Y; Sabater S; Torne A; Arenas M
J Contemp Brachytherapy; 2018 Feb; 10(1):40-46. PubMed ID: 29619055
[TBL] [Abstract][Full Text] [Related]
35. Computed tomography-based image-guided brachytherapy for cervical cancer: correlations between dose-volume parameters and clinical outcomes.
Kusada T; Toita T; Ariga T; Maemoto H; Hashimoto S; Shiina H; Kakinohana Y; Heianna J; Nagai Y; Kudaka W; Aoki Y; Murayama S
J Radiat Res; 2018 Jan; 59(1):67-76. PubMed ID: 29186565
[TBL] [Abstract][Full Text] [Related]
36. Dose-volume histogram parameters of high-dose-rate brachytherapy for Stage I-II cervical cancer (≤4cm) arising from a small-sized uterus treated with a point A dose-reduced plan.
Nakagawa A; Ohno T; Noda SE; Kubo N; Kuwako K; Saitoh J; Nakano T
J Radiat Res; 2014 Jul; 55(4):788-93. PubMed ID: 24566721
[TBL] [Abstract][Full Text] [Related]
37. Dosimetric predictors of local control and complications in gynecologic transperineal implant patients: The medical college of wisconsin experience.
Zeitlin R; Yu G; Wheatley M; Morrow N; Rownd J; Rein L; Banerjee A; Bedi M; Erickson B
Brachytherapy; 2022; 21(1):94-109. PubMed ID: 34937684
[TBL] [Abstract][Full Text] [Related]
38. Relationship of Urethral Dose and Genitourinary Toxicity Among Patients Receiving Vaginal High Dose Rate Interstitial Brachytherapy.
Cozma AI; Martell K; Ravi A; Barnes E; Donovan E; Paudel M; Leung E; Taggar A
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):773-779. PubMed ID: 34092463
[TBL] [Abstract][Full Text] [Related]
39. Multivariate normal tissue complication probability modeling of vaginal late toxicity after brachytherapy for cervical cancer.
Annede P; Mailleux H; Sfumato P; Ferré M; Autret A; Varela Cagetti L; Macagno A; Fau P; Chargari C; Tallet A; Resbeut M; Zemmour C; Gonzague L; Boher JM
Brachytherapy; 2018; 17(6):922-928. PubMed ID: 30061056
[TBL] [Abstract][Full Text] [Related]
40. Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer.
Yoshida K; Yamazaki H; Nakamura S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshikawa N; Uesugi Y; Shimbo T; Narumi Y; Yoshioka Y
J Gynecol Oncol; 2015 Jul; 26(3):179-84. PubMed ID: 25925294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
